Tagged with P

Global First published in ISPOR’s Value & Outcomes Spotlight magazine, Shirley V. Wang, PhD, MSc of Brigham and Women’s Hospital, Harvard Medical School, argues that there is an urgent need for transparency in health economics and outcomes research (HEOR). Wang posits that the growing reliance on real-world evidence (RWE) in healthcare…

Switzerland SpiroChem has evolved from a niche ETH Zurich spin-out into a global discovery partner recognised for tackling some of the most complex challenges in modern drug design. Over more than a decade, co-founder and CEO Thomas Fessard has steered the company’s transformation from a product-focused catalogue into a solution-driven, modality-agnostic…

Switzerland Giancarlo Benelli, SVP, Head of Europe at BeOne Medicines (BeOne), draws on nearly three decades of pharmaceutical leadership to drive the company’s rapid growth in oncology and haematology in Europe, with flagship assets like zanubrutinib and tislelizumab. Over the last few years, BeOne has greatly expanded its clinical trials in…

China This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights Atom Bioscience’s HKEX IPO, Ark Biosciences’ pipeline funding, Mabwell’s USD 1 billion siRNA deal, HiDiamond Bio’s Pre-Series A, and Enrui Kainuo’s CAR-NK cell therapy financing, alongside updates on IASO Bio’s CAR-T long-term data, Fosun’s breast cancer drug…

Europe Rainer Westermann of European life science venture capital lobby group, the Life Sciences Acceleration Alliance, lays out a policy roadmap for how innovative European pharma can continue to grow and thrive against a backdrop of trade uncertainty and precarious US-EU relations.   The US/EU trade deal was presented as necessary…

LatAm Dr Jarbas Barbosa, Director of the Pan American Health Organization (PAHO), discusses the organisation’s evolution from pandemic response to comprehensive health system transformation, regional production capabilities, and the imperative for multilateral cooperation in an increasingly fragmented global landscape.   The Americas, in their extraordinary diversity, are a living laboratory Could…

Switzerland Neil Archer, Executive Vice President International at Madrigal, discusses the company’s pioneering role in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), a progressive liver disease with no prior approved therapies. He shares insights on Madrigal’s breakthrough first-in-class treatment, the challenges of launching an entirely new therapeutic category, and the bold international expansion…

Switzerland Kasha Witkos, Senior Vice President and Head of International Business at Alnylam Pharmaceuticals, shares her journey from academic researcher to global biotech leader, driven by personal family experience of chronic disease.  Witkos highlights Alnylam’s pioneering role in delivering RNA interference (RNAi) technology to patients around the world, the company’s global…

China 3D Medicines has charted a deliberate path from domestic clinical execution to global oncology innovation. Since its IPO, the company has sharpened its focus on differentiated assets like Envafolimab, while expanding into radioligand and mRNA-based platforms with broad therapeutic potential. Chairman and CEO Dr John Gong outlines how strategic discipline,…

Switzerland Philippe de Saab, Vice President, Vision Care at Bausch + Lomb, outlines the company’s strategy amid rising global demand for contact lenses. He highlights innovations in contact lenses, a localised approach across 50 diverse markets and efforts to expand patient access through professional partnerships – all built on Bausch +…

USA Chris Molineaux, CEO of Life Sciences Pennsylvania, highlights Pennsylvania’s emergence as a leading life sciences hub, with 3,000+ companies, top NIH-funded universities, and global partnerships drawing investment. He notes that Pennsylvania’s pharmaceutical heritage and growing cell and gene therapy expertise – in addition to other cutting-edge modalities – offer unique…

Switzerland Marcel Imwinkelried, CEO of Siegfried, leads a CDMO specialising in small molecules with comprehensive global manufacturing capabilities. His “Evolve Plus” strategy focuses on operational excellence, selective biologics growth, and disciplined acquisitions to ensure sustainable expansion. Under his leadership, Siegfried prioritises innovation, sustainability, and talent development to deliver lasting value to…